Sign Up to like & get
recommendations!
1
Published in 2019 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2019.1555460
Abstract: ABSTRACT Background: Immunomodulator (IMID) and proteasome inhibitor (PI) triplet frontline therapy (FT) in newly diagnosed multiple myeloma (NDMM) trials improve overall survival (OS); reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM…
read more here.
Keywords:
newly diagnosed;
imid triplet;
triplet;
multiple myeloma ... See more keywords